A PHASE 2, MULTICENTER, MULTI-COHORT, OPEN-LABEL STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE OR POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE AND DARATUMUMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Celgene Corporation
Start Date
March 13, 2017
End Date
May 31, 2022
Administered By
Duke Cancer Institute
Awarded By
Celgene Corporation
Start Date
March 13, 2017
End Date
May 31, 2022